干眼症新药热销，3ml售价近200元！专家：并非人人适用！

Core Viewpoint - The inclusion of perfluorohexyl octanoate eye drops "Hengqin" in the medical insurance directory has garnered significant attention from individuals suffering from dry eye syndrome, highlighting the growing demand for effective treatments in this area [1][5]. Group 1: Product Information - Perfluorohexyl octanoate eye drops were approved for market release in July 2025 and are designed to stabilize the tear film and prevent excessive evaporation of tear fluid [5]. - The eye drops are priced at 190 yuan for a 3ml bottle, significantly higher than traditional artificial tears, yet they have seen robust sales, exceeding 10,000 units [5]. - The product is specifically indicated for treating dry eye syndrome related to meibomian gland dysfunction (MGD) and is not suitable for all dry eye patients [6]. Group 2: Market Demand and Usage - Over 60% of patients consulting for dry eye symptoms in outpatient settings are seeking treatment, indicating a high prevalence of the condition [5]. - Dry eye syndrome is characterized by insufficient tear production and instability of the tear film, leading to symptoms such as dryness, burning, and discomfort [5][6]. - The treatment landscape for dry eye has traditionally focused on symptom relief, with artificial tears being the most common solution, although they often lack long-lasting effects [6]. Group 3: Treatment Recommendations - Experts recommend a stepwise approach to treating dry eye, emphasizing the need for individualized treatment based on the type and severity of the condition [6]. - Other treatment options include non-steroidal anti-inflammatory drugs, physical therapies, and surgical interventions for severe cases [7]. - Lifestyle modifications, such as using humidifiers and adhering to the "20-20-20" rule for eye care, are also advised to mitigate symptoms [7].